Review Article of American Journal of Biotechnology and Bioscience
ASPERGILLOSIS AND ADVANCES IN ITS TREATMENT IN THE LAST DECADE: A LITERATURE REVIEW
Marcos Antônio Cavalari.Souza¹*, Paula Miranda Castro¹, Lucas Moreira Guerra¹, Pedro Rafael Del Santo Magno².
¹Centro Universitário das Faculdades Associadas de Ensino (UNIFAE); ²Hospital e Maternidade Sepaco
Introduction: Invasive aspergillosis (AI) remains a fatal infection and difficult to treat in immunocompromised patients. Standard treatment is insufficient for these patients, often impairing their quality of life due to adverse effects, in addition to the short duration. Although mortality rates in patients with UA have decreased in the past two decades with the replacement of amphotericin B deoxycholate (AmB-D) with voriconazole as the first choice, treatment remains sub-ideal for patients due to adverse events and drug interactions with immunosuppressive drugs.
Objective: This study aims to carry out a literary review about the scientific productions that address the treatment of AI published in the last 10 years, comparing the success and effectiveness rates of the treatments.
Methodology: Through a literature review using the base dates PubMed, Lilacs and MedLine, accepting only articles published in the period 2010 to 2020, and only those in Portuguese or English, with 23 articles selected, of which 7 were included in this review.
Results and discussion: There was a prevalence of treatments with voriconazole, used in six of the seven studies reviewed, in addition to being part of the standard Brazilian treatment. Studies related to the treatment of UA are heterogeneous, making it difficult to compare effectively between publications. Well-designed controlled, randomized and multicenter clinical trials are needed to adequately address the issue of the usefulness of the approaches used in Brazil. In addition, combined therapies come in many different forms, requiring cumulative evidence to support the use of combined antifungal therapy in AI, as they are still conflicting and of moderate strength.
Keywords: Aspergillosis; Treatment; Aspergillus spp; Voriconazole; Amphotericin B.
How to cite this article:
Marcos Antônio Cavalari.Souza, Paula Miranda Castro, Lucas Moreira Guerra, Pedro Rafael Del Santo Magno. ASPERGILLOSIS AND ADVANCES IN ITS TREATMENT IN THE LAST DECADE: A LITERATURE REVIEW.American Journal of Biotechnology and Bioscience, 2021; 4:21. DOI: 10.28933/ajbb-2021-07-1805
1. FILHO, et al. Aspergilose cerebral em paciente imunocompetente. Arq Neuropsiquiatr. 2005; 63(4):1094-1098.
2. MEDENÇA, et al. Aspergilose pulmonar em paciente imunocompetente e previamente sadio. Revista da Sociedade Brasileira de Medicina Tropical. 2011; 44(1):124-126
3. ANDES D, et al. Drug-drug interaction associated with mold-active triazoles among hospitalized patients. Antimicrob Agents Chemother. 2016; 60:3398-406. doi: 10.1128/AAC.00054-16
4. NETT J, ANDES D. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect Dis Clin North Am. 2016; 30:51-83.
5. PEGHIN, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transplant International. 2010 116 (24): 5111–5118. doi: 10.1111/tri.12679.
6. WINGARD, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010. 116(24), 5111–5118. doi:10.1182/blood-2010-02-268151
7. SCHWARTZ, S; REISMAN, A; TROKE, P.F. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection. 2011 Jun;39(3):201-10. doi: 10.1007/s15010-011-0108-6.
8. BADDLEY, et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Medical Mycology. 2013. 51(2), 128–135. doi:10.3109/13693786.2012.690108
9. EGERER et al.: Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry. European Journal of Medical Research. 2012, 17:7.
10. RAAD II, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2014, http://dx.doi.org/10.1016/j.ijantimicag.2014.08.012.
11. MAERTENS, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016. Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9.
12. AL-BADRIYEH D, LIEW D, STEWART K, KONG DCM. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother [periódico na internet]. 2008 [acesso em 10 jun 2020]; 63(1):197-208
This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.